Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 14, 2017

View Archived Issues

Bayer and DKFZ disclose novel AhR antagonists for cancer

New rat model captures characteristics of AKT3 hemimegencephaly

Principia Biopharma begins clinical studies of PRN-1008 in ITP

Novel alphaVbeta3 antagonists show promise for osteoporosis

UMN Pharma returns influenza vaccine program rights to Protein Sciences

Allakos secures series B financing to advance its development programs

New formulation of Oncaspar approved in Europe

X-Chem enters research collaboration with Abilita Bio

reMYND and Novo Nordisk enter license agreement for ReS-39 in diabetes

FDA approves Pfizer's infliximab biosimilar Ixifi

Targeting potassium channel Kv7.2 may improve Dravet syndrome

Glenmark Pharmaceuticals' phase III study of Ryaltris meets primary endpoint

NIH grant supports IBBR's research into the TCR signaling mechanism

Positive first-in-human data for new complement C3 inhibitor AMY-10

Novel mutation in PIGQ gene tied to epileptic encephalopathy

Bristol-Myers Squibb and Ono Pharmaceutical sign license agreement for ONO-4578

JCR reports topline results from phase I/II study of JR-141 in Hunter's syndrome

Meiji and Kaketsuken to enter into memorandum of understanding regarding new company

Novel PD-1 signaling inhibitors presented by Institute of Materia Medica of Beijing

Institute of Materia Medica of Beijing divulges salinomycin oxime ether derivatives

SLC22A12 inhibitors described in Institute of Materia Medica of Beijing patent

Scancell and Cancer Research UK partner to progress SCIB-2 into phase I/II study

Idera Pharmaceuticals patents antisense oligonucleotides for cancer

Vertex enters development agreement with CRISPR Therapeutics for gene-editing treatment

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
New 5-HT2C receptor agonists reported in Hansoh patent
BioWorld Science
Researchers from Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have disclosed tricyclic compounds acting as 5-HT2C receptor...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...